Pinnacle Associates Boosts Regeneron Pharmaceuticals Holdings

Investment firm increases stake in biotech company by 22.1% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Pinnacle Associates Ltd., an investment management firm, increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.1% during the third quarter, according to a recent SEC filing. The fund now owns 84,191 shares of the biopharmaceutical company's stock, valued at approximately $47.34 million.

Why it matters

Regeneron Pharmaceuticals is a leading biotech company known for its innovative drug discovery technologies and pipeline of biologic therapies. The increase in Pinnacle Associates' stake suggests the firm sees strong growth potential in Regeneron's business and future prospects.

The details

According to the 13F filing, Pinnacle Associates acquired an additional 15,265 shares of Regeneron Pharmaceuticals during the third quarter, bringing its total position to 84,191 shares. This represents approximately 0.08% of Regeneron's outstanding shares. The investment firm cited the company's strong product portfolio and research capabilities as reasons for increasing its stake.

  • Pinnacle Associates filed its 13F report for the third quarter of 2026 on March 8, 2026.

The players

Pinnacle Associates Ltd.

An investment management firm that focuses on public equities and manages over $5 billion in assets.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that specializes in discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Pinnacle Associates' increased stake in Regeneron Pharmaceuticals suggests the firm's confidence in the biotech company's long-term growth potential. As a leading innovator in the pharmaceutical industry, Regeneron's continued success could be a positive sign for the broader sector.